Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
13.23
+0.56 (4.42%)
At close: Sep 26, 2025, 4:00 PM EDT
12.43
-0.80 (-6.05%)
After-hours: Sep 26, 2025, 5:42 PM EDT
Aardvark Therapeutics Employees
Aardvark Therapeutics had 22 employees as of December 31, 2024.
Employees
22
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,665,364
Market Cap
287.05M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 22 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AARD News
- 4 days ago - Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum - GlobeNewsWire
- 23 days ago - Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 23 days ago - Aardvark Therapeutics, Inc. (AARD) Presents At Cantor Fitzgerald Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 4 weeks ago - Aardvark Therapeutics to Present at Upcoming Investor Conferences in September - GlobeNewsWire
- 6 weeks ago - Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates - GlobeNewsWire
- 6 weeks ago - Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy - GlobeNewsWire
- 2 months ago - Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) - GlobeNewsWire
- 3 months ago - Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference - GlobeNewsWire